Proteasome Inhibitors: Structure and Function

Since 2003, with the FDA approval of bortezomib, proteasome inhibitors have changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Since that time, two additional proteasome inhibitors, carfilzomib and ixazomib have been approved, with other agents and combinations currently under investigation. Proteasomes degrade ubiquitinated proteins or substrates through the ubiquitin-proteasome pathway, a pathway that is utilized in multiple myeloma due to the high protein turnover with immunoglobulin production.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research